As anticipated by the industry on both sides of the English Channel, the Department of Health and Social Care (DHSC) has issued its latest guidance to suppliers on the government’s no-deal contingency planning. The guidance provides operational details on shipping routes between the EU and the UK and the introduction of the Dedicated Shipment Channel to ensure an uninterrupted supply of medical products.

To minimise the risk of significant delays to medicines and medical devices entering the UK, the Government has secured additional ferry capacity as an alternative supply route. Suppliers will be able to purchase tickets for the government-secured capacity and should have already received an email to enrol onto the ‘DHSC eXchange’ portal. The Dedicated Shipment Channel involves a logistic operation set up by the DHSC to move products into the UK in the event a supplier’s arrangements are disrupted by Brexit. Registration for the Channel is now live and can be accessed here. Eligibility is subject to registration and should be completed as soon as possible.

The above builds upon the DHSC’s recommendations for suppliers to source alternative routes across the English Channel in the event of a no-deal scenario and the Office for Life Science’s notification that the pre-registration scheme to use the priority routes would soon be open.

The guidance can be found here. Further details on the Dedicated Shipment Channel can also be accessed here.


Julia is a key member of the Firm's Healthcare Practice Group, at the London, EMEA and global level. She advises both domestic and international companies in the medtech, pharma and healthcare sectors on a wide range of regulatory and general compliance matters including industry code compliance, interactions with healthcare professionals and patients, genetic testing, clinical research, virtual health, CQC registrations, market access, biological products, patient support programs, digital health applications, borderline products, pre-licence communications, CE marking, marketing authorisations. Julia sits on the Legal Committees of the Association of British HealthTech Industries and the Association of the British Pharmaceutical Industry, and is a spokesperson for the Firm on healthcare issues arising in connection with Brexit.


Els Janssens is a senior associate in our Abu Dhabi office and provides knowledge management support to Baker & McKenzie’s global and MENA Pharmaceutical and Healthcare industry group. Els started her career in 2000 at Baker and McKenzie in Brussels focusing her practice on pharmaceutical law and commercial litigation. She has worked six years in London as a legal adviser with the European Medicines Agency (EMA). During this period she has supported the EMA’s activities in medicines oversight and regulation and interacted with the European Commission on legal matters relating to medicinal products. She also worked one year as senior legal counsel in Johnson & Johnson’s European legal department providing regulatory advice regarding various medicinal products and supporting the public affairs function on new legislation.

Write A Comment